Positive results from a clinical trial in adults with grade 2 glioma were a Late-Breaking Abstract at the Society of Neuro-Oncology (SNO) 2024 Annual Meeting. The results have an immediate clinical impact, as this is the first evidence from a randomized phase 3 study that temozolomide chemotherapy improves long-term survival for these patients. Radiation therapy plus chemotherapy is the routine initial treatment for patients with this slow-growing form of brain cancer. Some receive PCV chemotherapy based on evidence of benefit from a prior trial. Others receive temozolomide, a chemotherapy pill, because it is less toxic for patients and more manageable for oncologists to administer. However, until E3F05, there was no supporting evidence in grade 2 gliomas that temozolomide was beneficial. The 10-year survival rate was 70% with the combined treatment compared to 47% with radiation alone. 

Colorectal cancer screening is an effective tool for catching the disease early when it's most treatable, yet it is underutilized at federally qualified health centers (FQHC). A new study by UNC Lineberger Comprehensive Cancer Center researchers demonstrated that a targeted intervention that paired mailing at-home colorectal cancer screening kits with coordinated follow-up tripled screening completion rates compared to usual care at FQHCs

For this inaugural edition of the Gustave Roussy Prize, applications must be submitted by December 20, 2024, at the following link: https://forms.office.com/e/rBSaqphxwG 

A recent study published in Molecular Biomedicine has revealed the promising therapeutic potential of tumor-infiltrating lymphocytes (TILs) derived from metastatic lymph nodes in treating advanced cervical cancer. Conducted by researchers from the Biotherapy Center and Cancer Center of the First Affiliated Hospital of Zhengzhou University and Grit Biotechnology in Shanghai, the study provides crucial insights into personalized immunotherapy for patients with refractory solid cancers.